CRNX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
25.1M
+134.0%
10.7M
+74.2%
6.2M
+4208.4%
143.0K
-86.1%
1.0M
Cost of Revenue
154.0K
-23.0%
200.0K
-81.4%
1.1M
0
0
Gross Profit
25.0M
+137.0%
10.5M
+107.2%
5.1M
+3455.9%
143.0K
-86.1%
1.0M
Operating Expenses
157.4M
+4.3%
150.9M
+8.8%
138.8M
-2.8%
142.7M
+9.7%
130.1M
R&D
99.8M
-0.2%
100.1M
+17.7%
85.1M
-6.0%
90.5M
+12.7%
80.3M
SG&A
57.6M
+13.3%
50.8M
-5.3%
53.7M
+2.7%
52.3M
+4.9%
49.8M
Operating Income
-132459000
+5.6%
-140378000
-5.0%
-133666000
+6.3%
-142586000
-10.4%
-129112000
EBITDA
-131386000
+5.6%
-139218000
-4.9%
-132672000
+6.3%
-141574000
-10.5%
-128153000
Net Income
-120855000
+5.5%
-127845000
-4.1%
-122815000
+5.6%
-130091000
-12.5%
-115637000
EPS (Basic)
$-1.14
+7.3%
$-1.23
+4.7%
$-1.29
+6.5%
$-1.38
-12.2%
$-1.23
EPS (Diluted)
$-1.14
+7.3%
$-1.23
+4.7%
$-1.29
+6.5%
$-1.38
-12.2%
$-1.23
Shares (Diluted)
105.6M
+1.4%
104.1M
+9.4%
95.1M
+1.0%
94.2M
+0.5%
93.8M
Crinetics Pharmaceuticals (CRNX) โ€” Financials